Geron’s Imetelstat NDA Accepted by FDA for Anemia Treatment

Geron Corp (GERN) has released an update.

Geron Corporation’s New Drug Application for imetelstat was accepted by the FDA for the treatment of transfusion-dependent anemia in certain myelodysplastic syndromes patients, with a PDUFA action date set for June 16, 2024. An advisory committee meeting to discuss the application will be held virtually on March 14, 2024, and will be open to the public.

For further insights into GERN stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.